General BeOne Medicines announces voluntary agreement with U.S. Government to expand access to innovative cancer medicinesBy Healthcare Propulsion StaffSeptember 1, 20260 BeOne Medicines, Ltd., a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to…
Research U.S. Registry Data Confirm Liver Risk With Controversial Vasculitis DrugBy Healthcare Propulsion StaffAugust 25, 20260 The C5a complement inhibitor avacopan (Tavneos) was FDA-approved in 2021 to treat ANCA-associated vasculitis, but questions have been raised about…
